Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification
about
PSA and beyond: alternative prostate cancer biomarkersTumour Heterogeneity: The Key Advantages of Single-Cell AnalysisMicrornas in prostate cancer: an overview.Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancerNovel tools for prostate cancer prognosis, diagnosis, and follow-upBeyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer MeetingTMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers.Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.Enrichment of the Cancer Stem Phenotype in Sphere Cultures of Prostate Cancer Cell Lines Occurs through Activation of Developmental Pathways Mediated by the Transcriptional Regulator ΔNp63αDysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.Integrative enrichment analysis: a new computational method to detect dysregulated pathways in heterogeneous samples.Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate CancerHigh-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate CancerEssential elements of personalized medicine.Circulating tumor cells in prostate cancer.Precision medicine for prostate cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.Prostate Cancer Genetics: A Review.Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancyGene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.Circulating tumor cells in prostate cancer: Precision diagnosis and therapyThe context of prostate cancer genomics in personalized medicine.Diagnostic, Prognostic, and Predictive Molecular Biomarkers and the Utility of Molecular Imaging in Common Gastrointestinal TumorsPBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer.In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology
P2860
Q26770646-9BBFE9C8-0CF7-4F26-9B0C-4E35638F069EQ28066914-EBDB2FFD-17A0-4265-8E2F-F380A96B9395Q30234658-5EA88314-EF8A-4A5E-A618-FDA0CA3F4BDAQ30252065-0950011F-2D55-46A9-A442-199189A9844BQ30764223-250071CF-0703-4FDB-9B28-AD3A4ADE096BQ33625338-6DD48CEB-F573-4079-8528-7BB4C8A38778Q34617627-7FA680CF-EC6F-4C1B-9C06-6BB7687564B4Q35088099-A92ADE80-604F-4F17-BF08-556823B7575DQ35223291-D68BA6E7-6912-4AEF-A273-DA24A634165CQ35407284-DF7EC720-B259-47DA-B118-2C3E96575E5DQ35674175-BF9849FB-34AE-443E-B88D-A493FF530CE2Q35764986-EB66B39C-5884-443D-8DEE-AD956B11F872Q35837792-8B1B2070-91A8-4FBA-AA67-67BCAAF45978Q35903128-BC6A4B0C-7BEE-49EE-9352-9B3BDB1A7F00Q35996026-5FDC4479-9E82-4FB7-97DC-0386BE6FC405Q36468773-39A334F7-C13F-49F7-BC64-3B8659A55D11Q37540608-C1BA9502-0218-4C19-9D6F-4C60B16EB638Q38168685-206EC6B7-5DC8-434B-8B9A-E9BF6000ECEDQ38263711-779AE578-26B6-408B-B0FA-18BDF310BE6AQ38774228-B264A696-3062-4538-AB73-158DF7B901C2Q38881952-A93F303B-831D-4295-8888-D7297A71C234Q38967495-064F6B30-85D7-463C-A5BB-7FAD2554D608Q38995507-C8A3F8B6-6D40-4F0E-9F5E-645C67EC9172Q40356316-D178FE33-E632-4935-AA50-72CE11937081Q41142322-AC665A73-4C1D-445F-8AB2-4B33A99023C6Q41839243-EE17A8C3-E7BD-4E84-9DD5-7858BDACCB78Q41956282-6AE39A1A-1226-4E0C-BAFE-8C707F8A28FEQ52727709-BB67FC5B-27E8-4C74-9CE0-CEBC73255969Q53692348-5C0F1B22-617A-435B-95F2-9F96314A9066Q55095957-7445284E-7006-437F-8CAB-115F12704645Q59129138-AFFB7BBD-4537-430D-8A14-A036127E64DB
P2860
Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genomic profiling defines subt ...... for therapeutic stratification
@en
Genomic profiling defines subt ...... or therapeutic stratification.
@nl
type
label
Genomic profiling defines subt ...... for therapeutic stratification
@en
Genomic profiling defines subt ...... or therapeutic stratification.
@nl
prefLabel
Genomic profiling defines subt ...... for therapeutic stratification
@en
Genomic profiling defines subt ...... or therapeutic stratification.
@nl
P2093
P2860
P1476
Genomic profiling defines subt ...... for therapeutic stratification
@en
P2093
Jamie R Schoenborn
Pete Nelson
P2860
P304
P356
10.1158/1078-0432.CCR-12-3606
P407
P577
2013-05-23T00:00:00Z